报价延迟最少15分钟:2026/10/19 01:14 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.98 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-19.10/--
|
|
企业价值
256.01M
|
| 资产负债 |
|
每股账面净值
3.04
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
109.35M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden. |
